Brigatinib/Efficacy of Brigatinib

Brigatinib/Brigatinib is effective in treating ALK-positive non-small cell lung cancer (NSCLC) patients who have previously been treated with an ALK inhibitor drug called crizotinib or who have not been treated with an ALK inhibitor. It has been shown to be effective in treating ALK-positive non-small cell lung cancer in two major studies.

The first study involved 222 patients whose disease progressed despite prior treatment with crizotinib. Brigatinib was not compared with any other treatment or with placebo (a dummy treatment). Response to treatment is assessed using body scans and standardized criteria for solid tumors, with complete response being when a patient has no remaining signs of cancer. About 56% of patients who received 90 mg of brigatinib daily and increased to 180 mg after seven days showed a complete or partial response to the drug. Responses lasted about 14 months on average.

The second study involved 275 patients who had not previously received ALK inhibitor treatment. In the study, patients who received brigatinib took an average of 24 months for their disease to worsen, compared with 11 months for those who received crizotinib.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).